TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16041631

Group type: EXPERIMENTAL
Intervention: Lidocaine 4% cream (LMX4)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and prilocaine 2.5% (EMLA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dorsal penile block (DPNB)
Number of subjects: 54
Study: 11843784

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Pericardium 6 (p6) acupuncture
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 593

Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 593
Study: 9919320

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Patients who remained both depressed and physically disabled
Number of subjects: 542

Group type: COMPARATOR
Intervention: Patients whose depression and physical disability improved
Number of subjects: 542
Study: 7576976

Group type: EXPERIMENTAL
Intervention: [131I]MIBG and hyperbaric oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: [131I]MIBG treatment alone
Number of subjects: 0
Study: 2179782

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin 5000 units 2 hours before surgery and every 8 hours postoperatively (regimen I)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin 5000 units every 8 hours preoperatively (between two and nine doses) and every 8 hours postoperatively (regimen II)
Number of subjects: 304

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 304
Study: 7441675

Group type: EXPERIMENTAL
Intervention: Screening for depression, physician sensitization, and informational feedback to physicians
Number of subjects: 150
Study: 31629851

Group type: EXPERIMENTAL
Intervention: Simple lesion group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Complex lesion group
Number of subjects: 54
Study: 30358032

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids and vitamin D supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low-intensity resistance training
Number of subjects: 68
Study: 27718137

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 921
Study: 25978109

Group type: EXPERIMENTAL
Intervention: H2-rich water (0.9 L/day) for 10 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo water for 10 weeks
Number of subjects: 68
Study: 24028941

Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (beetroot juice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21876446

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 92

Group type: COMPARATOR
Intervention: dose reduction
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: granulocyte colony‐stimulating factor
Number of subjects: 92
Study: 18761097

Group type: EXPERIMENTAL
Intervention: 35 mg cortisol
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 17605632

Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg, i.v.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pamidronate (30 mg, i.v., for 2 consecutive days every 3 mo; n = 60)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neridronate (100 mg, i.v., for 2 consecutive days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Zoledronate (after crossover from pamidronate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neridronate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 90
Study: 14724101

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with a 5‐min ischemia followed by 5‐min perfusion before hepatic vascular exclusion
Number of subjects: 34
Study: 12391349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg vs Sumatriptan 50 mg
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: All doses of eletriptan vs Sumatriptan
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg vs both Sumatriptan doses
Number of subjects: 1008
Study: 10437990

Group type: EXPERIMENTAL
Intervention: Higher-dose methadone (mean dose 211 mg/d, range 110‐780 mg/d)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (mean dose 65 mg/d)
Number of subjects: 164
Study: 7495043

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2406861

Group type: COMPARATOR
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic antimicrobial agents
Number of subjects: 0
Study: 6986243

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine with antacid therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Antacids alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral cimetidine with antacids
Number of subjects: 27
Study: 31765932

Group type: EXPERIMENTAL
Intervention: Peer-group based intervention (n=206)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Self-management control group (n=196)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Peer-group based intervention
Number of subjects: 402
Study: 29480853

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - induced by 4 times of 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper arm, followed by 5-min intervals of reperfusion at 1 hour before PCI therapy.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group - an uninflated cuff around the arm.
Number of subjects: 161
Study: 27172434

Group type: EXPERIMENTAL
Intervention: Transdermal T gel (1.25 g, 2.5 g, 5.0 g, 10 g, or 15 g daily) plus acyline injections every 2 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo injections and transdermal gel
Number of subjects: 62
Study: 25209519

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% ointment (single doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ozenoxacin 1% ointment (multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ozenoxacin 2% cream (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream (multiple doses on intact and abraded skin)
Number of subjects: 0
Study: 23000583

Group type: EXPERIMENTAL
Intervention: LAB group (LAB‐G)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LAB with lactose group (L‐LAB‐G)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (C‐G)
Number of subjects: 15
Study: 20362902

Group type: EXPERIMENTAL
Intervention: Glass ionomer adhesive (Fuji I)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Composite resin adhesive (Transbond XT)
Number of subjects: 25
Study: 18156660

Group type: EXPERIMENTAL
Intervention: Whey-protein supplement (120 kcal, 30 g protein)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Noncaloric placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 17
Study: 15726879

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg oral dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12466928

Group type: EXPERIMENTAL
Intervention: Macro-adjustments in response to the relative probability of conflict trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micro-adjustments invoked by the commission of incidental errors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High probability of conflict trials
Number of subjects: 0
Study: 10403033

Group type: EXPERIMENTAL
Intervention: CPRV (n = 163)
Number of subjects: 330

Group type: COMPARATOR
Intervention: PVRV (n = 167)
Number of subjects: 330
Study: 7805119

Group type: EXPERIMENTAL
Intervention: Consupren (Czech preparation of cyclosporin A)
Number of subjects: 5
Study: 3182882

Group type: EXPERIMENTAL
Intervention: Ender pins
Number of subjects: 100

Group type: COMPARATOR
Intervention: Compression hip-screw
Number of subjects: 100
Study: 31189497

Group type: EXPERIMENTAL
Intervention: Demonstration
Number of subjects: 247

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 247
Study: 29649954

Group type: EXPERIMENTAL
Intervention: Retroperitoneal (RP) approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transperitoneal (TP) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal clamp position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clamp position inferior to the superior mesenteric artery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal function and mortality
Number of subjects: 0
Study: 29234745

Group type: EXPERIMENTAL
Intervention: Definitive abutment group (immediate loading)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Repeated abutment changes group (delayed loading)
Number of subjects: 80
Study: 25906754

Group type: EXPERIMENTAL
Intervention: Rich in polyphenols
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rich in LCn3
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rich in LCn3 and polyphenols
Number of subjects: 86
Study: 24499699

Group type: EXPERIMENTAL
Intervention: Aspherical IOL implantation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional sphere IOL implantation
Number of subjects: 96
Study: 21402400

Group type: EXPERIMENTAL
Intervention: Enrolled Hispanic women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dropout rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reasons for active refusal
Number of subjects: 0
Study: 19014072

Group type: EXPERIMENTAL
Intervention: Surgical treatment for OSA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 30
Study: 16764983

Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mouth-to-pocket-mask ventilation (MPV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mouth-to-face-shield ventilation (MFV)
Number of subjects: 70
Study: 12694632

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including a workshop in evidence‐based public health, a newsletter, access to a specially designed information service, relevant databases, and an electronic discussion list.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group received a letter declaring access to library services.
Number of subjects: 148
Study: 10885237

Group type: EXPERIMENTAL
Intervention: Drip-infusion of Diprivan (1% propofol emulsion)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Syringe-pump administration of Diprivan (1% propofol emulsion)
Number of subjects: 28
Study: 8813310

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Endometrial ablation
Number of subjects: 204
Study: 8316057

Group type: EXPERIMENTAL
Intervention: Garlic supplementation (600 mg/d of garlic powder for two weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3712428

Group type: EXPERIMENTAL
Intervention: Phone-prompt group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mail-prompt group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 30676223

Group type: EXPERIMENTAL
Intervention: Dynamic Leap Balance Test (DLBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Star Excursion Balance Test (SEBT)
Number of subjects: 36
Study: 29371672

Group type: EXPERIMENTAL
Intervention: Moderate alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No alcohol (sober)
Number of subjects: 0
Study: 27903994

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement, 1000 mg/d for 6 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (2 capsules a day) for 6 weeks
Number of subjects: 66
Study: 25661412

Group type: EXPERIMENTAL
Intervention: Endotracheal suction
Number of subjects: 122

Group type: COMPARATOR
Intervention: No suction
Number of subjects: 122
Study: 23895165

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 combined with selenium
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 20819135

Group type: EXPERIMENTAL
Intervention: Low bulb obturators
Number of subjects: 13

Group type: COMPARATOR
Intervention: High bulb obturators
Number of subjects: 13
Study: 19068205

Group type: EXPERIMENTAL
Intervention: Beta-blocker bisoprolol (n=55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine drugs (ACE Inhibitors, diuretics, vasodilator drugs) (n=55)
Number of subjects: 110
Study: 16897997

Group type: EXPERIMENTAL
Intervention: S-1 (2-week administration followed by 1-week rest)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFT (4-week administration followed by 2-week rest)
Number of subjects: 0
Study: 12627181

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Red wine supplementation
Number of subjects: 21
Study: 10709813

Group type: EXPERIMENTAL
Intervention: Group 1 (patients with daytime complaints)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group 2 (patients without daytime complaints)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study: 9663830

Group type: EXPERIMENTAL
Intervention: Misoprostol (600-2400 microg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Single-dose misoprostol (400 microg)
Number of subjects: 18
Study: 8409784

Group type: EXPERIMENTAL
Intervention: Palpation for osseous pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palpation for soft tissue pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surface EMG measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dermothermograph measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidimensional index of lumbar abnormality
Number of subjects: 0
Study: 3947108

Group type: EXPERIMENTAL
Intervention: CQ PSK in alternate doses (Group B)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CQ + PSK in alternate doses (Group D)
Number of subjects: 168

Group type: COMPARATOR
Intervention: CQ intermittently (Group A)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Controls (Group C)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Controls (Group E)
Number of subjects: 168
Study: 30340619

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wellness education (active control)
Number of subjects: 75
Study: 27485109

Group type: EXPERIMENTAL
Intervention: Deep sequencing (DS) of BCR-ABL1
Number of subjects: 51
Study: 24646123

Group type: EXPERIMENTAL
Intervention: Intervention package including mobilization of family support, emergency funds, transport options, training for health workers, and security provisions.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Control group (no intervention package)
Number of subjects: 5000
Study: 22182254

Group type: COMPARATOR
Intervention: Normal weight women
Number of subjects: 112

Group type: COMPARATOR
Intervention: Overweight women
Number of subjects: 112

Group type: COMPARATOR
Intervention: Obese women
Number of subjects: 112

Group type: COMPARATOR
Intervention: Normal weight individuals
Number of subjects: 112

Group type: COMPARATOR
Intervention: Overweight individuals
Number of subjects: 112

Group type: COMPARATOR
Intervention: Obese individuals
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Type II sarcopenic individuals
Number of subjects: 112
Study: 19909829

Group type: EXPERIMENTAL
Intervention: IV ibandronate injections (2 mg every 2 months, 3 mg every 3 months)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: IV ibandronate (3 mg)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Oral ibandronate (2.5 mg daily)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Oral or IV placebo
Number of subjects: 1395
Study: 18822932

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS) for 3 days every 2 weeks for 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MDI with CGMS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wide blood glucose fluctuations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions aimed at reducing fluctuations
Number of subjects: 32
Study: 16037147

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 115
Study: 12459940

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg/day for 48 weeks)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Etidronate (200 mg/day for 2 weeks followed by 10-week medication-free periods)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 235

Group type: COMPARATOR
Intervention: Etidronate
Number of subjects: 235
Study: 10673950

Group type: EXPERIMENTAL
Intervention: Optimum patient positioning for left‐sided tumours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard patient treatment position for left‐sided tumours
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3-dimensional planning with optimum treatment position for left‐sided tumours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard glancing field set-up for left‐sided tumours
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Optimum patient positioning for right‐sided tumours
Number of subjects: 26
Study: 9180955

Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux assessment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lung function assessment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Relationship assessment between gastroesophageal reflux and pulmonary damage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gastric acid secretion assessment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Steatorrhea assessment
Number of subjects: 10
Study: 1503823

Group type: EXPERIMENTAL
Intervention: rgp160 vaccination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 3900301

Group type: COMPARATOR
Intervention: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: CHOP-levamisole
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: CHOP-levamisole-BCG
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 715

Group type: COMPARATOR
Intervention: CHOP chemotherapy alone
Number of subjects: 715
Study: 31383385

Group type: EXPERIMENTAL
Intervention: 400 mg oral ibuprofen
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 600 mg oral ibuprofen
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 800 mg oral ibuprofen
Number of subjects: 225
Study: 29220345

Group type: EXPERIMENTAL
Intervention: T‐provisional stenting
Number of subjects: 146

Group type: COMPARATOR
Intervention: mini‐crush technique
Number of subjects: 146
Study: 26172529

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 24613450

Group type: COMPARATOR
Intervention: Weekly oral alendronate (70 mg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (1-time 5 mg)
Number of subjects: 101
Study: 22588319

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 382

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 382
Study: 19909947

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (1.5 mg) administered orally
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (1.5 mg) administered vaginally
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 27
Study: 18663546

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 22
Study: 15769243

Group type: EXPERIMENTAL
Intervention: Negotiators who reached an impasse in prior negotiations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negotiators who reached an initial agreement in prior negotiations
Number of subjects: 0
Study: 11826199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 10519745

Group type: EXPERIMENTAL
Intervention: Midazolam sedation with lignocaine 2%, adrenaline 1:50,000, and vasopressin 0.25 IU
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lignocaine 2%, adrenaline 1:50,000, and vasopressin 0.25 IU alone (anesthetic group)
Number of subjects: 75
Study: 7500174

Group type: EXPERIMENTAL
Intervention: High energy nutrient dense supplement provided by a dietitian
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group receiving visits only
Number of subjects: 50
Study: 1771281

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40
Study: 6349453

Group type: EXPERIMENTAL
Intervention: Real peritoneal dialysis (48 hours weekly, 1.5-hour cycle times, 2-litre exchanges by machine)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham peritoneal dialysis (recycling the same 2 litres of 1.5% continuous ambulatory peritoneal dialysis fluid, 1.5-hour cycle times for 48 hours weekly)
Number of subjects: 5
Study: 30956021

Group type: EXPERIMENTAL
Intervention: Educational video after face-to-face education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face-to-face education only
Number of subjects: 60
Study: 29710059

Group type: EXPERIMENTAL
Intervention: Gum-containing thickener
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starch-based thickener
Number of subjects: 0
Study: 27575034

Group type: EXPERIMENTAL
Intervention: Bupivacaine with triamcinolone (steroids)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Bupivacaine without steroids (control)
Number of subjects: 910